Welcome to our dedicated page for Indaptus Therapeutics news (Ticker: INDP), a resource for investors and traders seeking the latest updates and insights on Indaptus Therapeutics stock.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) is a pioneering pre-clinical biotechnology company focused on developing revolutionary treatments for cancer and certain infectious diseases. By harnessing the body’s innate and adaptive immune responses, Indaptus aims to cure disease through its proprietary platform that leverages bacteria's natural ability to activate both immune pathways.
The company’s flagship candidate, Decoy20, demonstrates significant promise in pre-clinical trials, showcasing single-agent activity and durable anti-tumor responses. These trials span various cancer models, including colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma. Indaptus' technology involves the use of attenuated and killed non-pathogenic Gram-negative bacteria to safely elicit broad immune responses.
In line with its commitment to transparency and education, Indaptus actively engages with the public through social media platforms. The company shares updates on its groundbreaking research, educational content about cancer immunotherapy, and behind-the-scenes insights into its scientific progress. This engagement aims to build a community passionate about medical advancements.
Indaptus has recently advanced its innovative immunotherapy for the treatment of solid metastatic tumors into Phase 1 human trials. The safety and efficacy of Decoy20 in these trials have been promising, allowing the company to progress to multi-dosing regimens. This phase aims to further explore the safety and potential benefits of repeated Decoy20 administrations.
With a strong foundation built on over a century of immunotherapy advancements, Indaptus Therapeutics is poised to make significant strides in cancer and viral infection treatment. The company’s technology has shown potential in pre-clinical models to eradicate tumors when combined with other therapies, such as anti-PD-1 checkpoint inhibitors and low-dose chemotherapy.
Indaptus’ forward-looking strategy includes ongoing research and development activities, aiming to demonstrate the utility of its technology for treating solid tumors and chronic viral infections. The company's innovative approach, coupled with a robust pre-clinical pipeline, positions it uniquely in the biotechnology landscape, making it a noteworthy entity for investors and researchers alike.
Indaptus Therapeutics recently announced that the FDA has cleared its IND application for a Phase 1 clinical trial of Decoy20 in patients with advanced solid tumors. Scheduled to start in the second half of 2022, the trial aims to evaluate the safety and preliminary efficacy of Decoy20, which targets tumors resistant to current therapies. Decoy20's unique technology mobilizes both innate and adaptive immune responses without inducing significant side effects. The trial will utilize a dose escalation design, and the therapy could potentially treat various cancers, including pancreatic and colorectal carcinomas.
Indaptus Therapeutics (Nasdaq: INDP) announced that CEO Jeffrey A. Meckler will present a corporate overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 8:30 AM ET. A live webcast will be available on the company's website and will be archived for 90 days.
Indaptus focuses on immunotherapy, utilizing patented technology that activates innate and adaptive immune cells to combat tumors and viral infections, demonstrating potential in preclinical models against chronic HBV and HIV.
Indaptus Therapeutics has submitted an Investigational New Drug (IND) application for Decoy20, aimed at treating solid tumors, with a Phase 1 clinical trial expected to start in 2022. The submission signifies a crucial step in the development of Decoy20, a dual Toll-like receptor (TLR) agonist that shows promise in activating immune responses against cancers. Financially, the company reported a loss per share of $0.41 for Q1 2022, along with increased R&D and administrative expenses, totaling $3.4 million. Cash reserves decreased to $36.2 million from $39.1 million in Q4 2021.
Indaptus Therapeutics (Nasdaq: INDP) announced that Dr. Michael J. Newman will present at the 2nd Annual Chronic HBV Drug Development Summit from April 25-27, 2022, in Boston, MA. The presentation is titled Driving Pre-Clinical Anti-HBV Activity With a Novel Multi-TLR Agonist Therapeutic Vaccine and will occur on April 27, 2022, at 12:00 PM ET. The summit aims to advance antiviral and immunotherapy development for chronic hepatitis B virus (HBV) treatment.
Indaptus Therapeutics (Nasdaq: INDP) announced that CEO Jeffrey Meckler will present at the Maxim Group 2022 Virtual Growth Conference on March 28, 2022, at 9:00 a.m. ET. The presentation will be pre-recorded, and an audio webcast will be accessible for 90 days via Indaptus' website. The company focuses on immunotherapy solutions leveraging patented technology involving non-pathogenic bacteria to activate immune responses for anti-tumor and anti-viral applications. Indaptus has successfully manufactured its lead candidate, Decoy20, and has completed various IND enabling studies.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) reported its financial results for Q4 and the year ending December 31, 2021. R&D expenses rose 150% to $1 million for Q4, while total R&D costs decreased 4% to $2.5 million for the year. G&A expenses surged 475% to $2.3 million in Q4, totaling $5.2 million annually, mainly due to payroll and public company costs post-Decoy merger. The company recorded a loss per share of $1.89 and had $39.1 million in cash as of year-end. Net cash used in operating activities ballooned to $11.3 million. Financing activities generated $48.3 million in 2021.
Indaptus Therapeutics (Nasdaq: INDP) announces that Dr. Michael J. Newman will present at the 3rd Annual STING & TLR-Targeting Therapies Summit from March 22-24, 2022. The presentation titled “Eradication of Established Tumors with Induction of Innate & Adaptive Immunological Memory” is scheduled for March 24 at 11:30 AM ET. Dr. Newman will also participate in a panel discussion on the best modalities for PRR-pathway targeting later that day at 1:30 PM ET. Indaptus focuses on innovative immunotherapy solutions with a patented technology that combines non-pathogenic bacteria to enhance immune response.
Indaptus Therapeutics (Nasdaq: INDP) announced that CEO Jeffrey Meckler will present at the 34th Annual ROTH Conference on March 14-15, 2022. An audio webcast of this presentation is available here and on the company's website, where it will be archived for 90 days. Indaptus focuses on immunotherapy, employing a multi-targeted approach for anti-tumor and anti-viral responses.
Indaptus Therapeutics (Nasdaq: INDP) announced CEO Jeffrey Meckler will present at the H.C. Wainwright BioConnect 2022 Virtual Conference on January 10 at 7:00 a.m. ET. The presentation will be pre-recorded and available via an audio webcast on the company's website, archived for approximately 90 days. Indaptus focuses on immunotherapy, using patented technology to activate immune responses for anti-tumor and anti-viral treatments. Their lead candidate, Decoy20, has undergone successful GMP manufacturing and is progressing with IND enabling studies.
Indaptus Therapeutics (Nasdaq: INDP) announces Dr. Boyan Litchev as the new Chief Medical Officer, effective January 31, 2022. Dr. Litchev brings over 20 years of experience in clinical oncology and medical leadership, having previously served at Shoreline Biosciences and Poseida Therapeutics. He will lead clinical strategies and the upcoming Phase 1 study of Decoy20, anticipated in 2022. The appointment is seen as a pivotal move towards advancing Indaptus's innovative immunotherapy platform aimed at treating various diseases through enhanced immune activation.
FAQ
What is the current stock price of Indaptus Therapeutics (INDP)?
What is the market cap of Indaptus Therapeutics (INDP)?
What does Indaptus Therapeutics, Inc. do?
What is Decoy20?
What makes Indaptus Therapeutics' technology unique?
What are the current projects of Indaptus Therapeutics?
What recent achievements has Indaptus Therapeutics made?
How does Indaptus Therapeutics engage with the public?
What types of cancer has Decoy20 shown promise against?
How does Indaptus’ technology work?
What is the goal of Indaptus Therapeutics?
Where can I find more updates on Indaptus Therapeutics?
